Novo Nordisk Teams Up with OpenAI
Novo Nordisk, the Danish pharmaceutical conglomerate, announced plans to implement AI solutions from OpenAI to accelerate drug development.
The company announced a “strategic” partnership, citing expected benefits such as upskilling staff and enhancing knowledge about artificial intelligence.
According to the agreement, OpenAI will support Novo Nordisk in improving efficiency in production, supply chain, distribution, and corporate operations.
“Novo Nordisk will be at the forefront of AI-driven transformation in the healthcare sector and will be able to deliver new treatments to patients faster,” reads the official statement.
“The partnership will use advanced AI capabilities for analysis of complex data sets, identifying promising drug candidates, and shortening the time required to move from research to patient use,” added the statement.
As stated, “the partnership was established with strict data protection, corporate governance, and human oversight principles to ensure ethical and compliant use of these solutions.”
Mike Doustdar, CEO and President of Novo Nordisk, emphasizes that the company is striving for a leadership position in the era of the “new age of healthcare.”
“Millions of people suffering from obesity and diabetes need access to treatments, and we know they are still waiting for those that could change their lives,” Doustdar said.
“Integrating AI into our daily work allows us to analyze data sets at a scale that was previously impossible, identify patterns we didn’t see before, and test hypotheses faster than ever. This means discovering new therapies and bringing them to market faster than ever before,” he added.
Also Sam Altman, CEO of OpenAI, highlighted the importance of AI-based collaboration, which “can help people live better and longer.”
Doustdar assured that AI implemented in Novo Nordisk’s structures will not replace scientists but will only “enhance their capabilities.”
In September of last year, he announced a 11% workforce reduction, roughly 9,000 employees.
The company’s spokesperson, quoted by Bloomberg, said employees had previously had access to a specialized version of ChatGPT.
See also: Novo Nordisk shares or Eli Lilly? This sector “should find a place in a long‑term investment portfolio,” says an expert
Novo Nordisk Shares Down. Another Impulse Approaching?
The price of Novo Nordisk shares closed on Monday, April 13, down 1.23% to 37.98 USD.
Pre‑market trading reached 39,10 USD after a rise of 2,95%.
Since the beginning of the year, the company’s shares have fallen by 26,41%.
Expected benefits from the partnership may only appear at the end of the year, in line with the then‑planned full integration of OpenAI into Novo Nordisk, after earlier pilot programs.
The Danish manufacturer did not disclose any financial terms of the agreement.
Last year, the company chose a similar partnership with Nvidia Corporation.
Chart. Novo Nordisk share price (NYSE)
Source: TradingView.
Read also: Novo Nordisk shares sink! Two‑digit drop after a gloomy company announcement
See also: 2026 Stock Exchange is preparing a surprise? “Investors should ensure their portfolios are ready for an upward trend”
